- Home
- TPCS vs RLMD Comparison
TPCS vs RLMD Comparison
Compare TPCS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- RLMD
- Stock Information
- Founded
- TPCS 1956
- RLMD 2004
- Country
- TPCS United States
- RLMD United States
- Employees
- TPCS N/A
- RLMD N/A
- Industry
- TPCS Metal Fabrications
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- TPCS Industrials
- RLMD Health Care
- Exchange
- TPCS Nasdaq
- RLMD Nasdaq
- Market Cap
- TPCS 51.4M
- RLMD 52.8M
- IPO Year
- TPCS N/A
- RLMD N/A
- Fundamental
- Price
- TPCS $5.36
- RLMD $1.62
- Analyst Decision
- TPCS
- RLMD Buy
- Analyst Count
- TPCS 0
- RLMD 3
- Target Price
- TPCS N/A
- RLMD $5.00
- AVG Volume (30 Days)
- TPCS 60.2K
- RLMD 1.8M
- Earning Date
- TPCS 08-21-2025
- RLMD 11-06-2025
- Dividend Yield
- TPCS N/A
- RLMD N/A
- EPS Growth
- TPCS N/A
- RLMD N/A
- EPS
- TPCS N/A
- RLMD N/A
- Revenue
- TPCS $33,424,000.00
- RLMD N/A
- Revenue This Year
- TPCS N/A
- RLMD N/A
- Revenue Next Year
- TPCS N/A
- RLMD N/A
- P/E Ratio
- TPCS N/A
- RLMD N/A
- Revenue Growth
- TPCS 3.78
- RLMD N/A
- 52 Week Low
- TPCS $2.05
- RLMD $0.24
- 52 Week High
- TPCS $6.25
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- TPCS 53.99
- RLMD 70.12
- Support Level
- TPCS $5.10
- RLMD $1.45
- Resistance Level
- TPCS $5.50
- RLMD $1.94
- Average True Range (ATR)
- TPCS 0.23
- RLMD 0.28
- MACD
- TPCS -0.33
- RLMD 0.02
- Stochastic Oscillator
- TPCS 93.21
- RLMD 72.82
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.